CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose ...

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial ...

Please provide your email address to receive an email when new articles are posted on . The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney ...

Heart failure patients treated with finerenone (Kerendia; Bayer AG) are more likely to have an early decline in kidney function than those treated with placebo, but the decline should not be construed ...